Adam Czerw, country manager of LEO Pharma Poland, discusses the impressive growth of the affiliate, especially since the global 2016 purchase of Astellas’ dermatology portfolio, as well as the encouraging development of LEO’s first ever reimbursed product on the Polish market. Furthermore, he highlights the key steps to further reward dermatological innovation and LEO’s role in establishing a more patient-centric Polish healthcare ecosystem.
LEO Pharma has, in recent years, been very active in partnerships and acquisitions, most importantly the 2016 purchase of Astellas’ dermatology range. How has this movement at the global level impacted the Polish affiliate?
"There is not a great focus in Poland on medical dermatology, and if you look at the actual amount spent in this therapeutic area, it is less than one percent of the total amount budgeted for reimbursement."
